Related Diseases
Insomnia
Description
LY2624803 is a 5-HT2A and histamine H1 receptor antagonist from Eli Lilly as part of its product line-up for therapeutics for the central nervous system. LY2624803 is in phase 2 of clinical trials for the treatment of chronic insomnia. LY2624803 has specific histamine and serotonin receptor antagonism and does not produce other unwanted side effects and it also penetrates into the brain well.
Chemical Formula
C22H25N3O3
Elemental Analysis
C, 69.64; H, 6.64; N, 11.07; O, 12.65
Synonym
LY-2624803; HY-10275; LY2624803; DB-7;
IUPAC/Chemical Name
1-Piperazinepropanoic acid, 4-dibenz(b,f)(1,4)oxazepin-11-yl-alpha,alpha-dimethyl-
InChi Key
UEFWDVMEDFCHGW-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H25N3O3/c1-22(2,21(26)27)15-24-11-13-25(14-12-24)20-16-7-3-5-9-18(16)28-19-10-6-4-8-17(19)23-20/h3-10H,11-15H2,1-2H3,(H,26,27)
SMILES Code
O=C(O)C(C)(C)CN1CCN(C2=NC3=CC=CC=C3OC4=CC=CC=C24)CC1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4℃ for short term (days to weeks), or -20℃ for long term (months).
HS Tariff Code
2934.99.9001